News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Claim: AstraZeneca PLC CEO Brennan’s Pay Too High; Spends Too Much on Lobbying
April 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BNET -- British corporate governance watchdog group PIRC is urging AstraZeneca shareholders to vote against management’s annual report and compensation plan because the company gives too much money to U.S. politicians and its top executives.
Twitter
LinkedIn
Facebook
Email
Print
People
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Layoff Tracker
BioAtla Cuts Some 70% of Workforce as Company Considers Options
March 3, 2026
·
60 min read
·
BioSpace Editorial Staff
MASH
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
March 3, 2026
·
2 min read
·
Tristan Manalac
Layoffs
BioAtla Axes 70% of Staff, Explores Strategic Options
March 2, 2026
·
1 min read
·
Angela Gabriel
IPO tracker
Generate Clocks Largest IPO Since 2024 With $400M Raise
February 27, 2026
·
5 min read
·
Tristan Manalac